Did Elan Corporation, plc (NYSE:ELN) Find A Cure For Down Syndrome?
At the beginning of September, Elan Corporation, plc (NYSE:ELN) announced the 1st first patient-dosing in a Phase IIA study of ELND005 in the treatment of Down syndrome. This study will evaluate safety and pharmacokinetics of two doses of ELND005 and a placebo in young-adults suffering from Down syndrome without dementia. This will include some specific cognitive & behavioral measures.
The first patient to be dosed at Dr Ira Lott’s site, who is
a Professor of Neurology & Pediatrics and a Down syndrome expert at Irvine’s University of California. Dr Lott said levitra vs viagra that they are pleased to commence this new study. In this particular field, the drug-development efforts have been very limited and that they look forward pharmacyexpress-viagra to studying whether ELND005 has the potential to act as a cognitive enhancer and improve the everyday-functioning of those suffering from Down syndrome.
In Friday’s trading session, Elan Corporation, plc (NYSE:ELN) stock rose by 0.52%. The opening price of the shares cialis strengths was $15.47 which rose to an intraday high of $15.69 and dropped to a close of $15.59. Approximately 24.93 million shares were traded on Friday and the average volume of shares traded over a 30 day period was $6.59 million. The 52-week low of the shares was $9.37 and the 52-week high was $15.92.
About the company
Elan Corporation, plc (NYSE:ELN) is a bio-tech company. It focuses on the discovery and development of advanced therapies in neuro-degenerative and auto-immune diseases. On 6 February 2013, it announced that it had entered into an asset-purchase agreement with Biogen Idec via which it will transfer all Tysabri IP and its related assets to Biogen Idec.
As kamagra kaufen of December 31 2012, there were around 72,700 patients on viagra for women Tysabri therapy across the world. On 20 December 2012, it completed separation of a sizeable segment of its drug-discovery business platform into a new, viagra for women publicly-traded company called Prothena Corporation.